Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen reported robust Q2 results, with adjusted EPS up 21% to $6.02 and revenue rising 9% to $9.18 billion, both exceeding analyst expectations, and subsequently raised its FY25 guidance. Despite this strong financial performance, AMGN shares are trading lower, as investor attention is primarily focused on the experimental weight-loss drug MariTide, with ongoing debate regarding its tolerability and competitive positioning ahead of Q4 2025 data readouts. Analysts, while acknowledging the MariTide focus, highlight Amgen's broader portfolio of successful assets and long-term growth catalysts, reiterating positive outlooks despite some near-term legacy product headwinds.

Analysis

Amgen delivered a robust second quarter, with adjusted EPS growing 21% year-over-year to $6.02 and revenue increasing 9% to $9.18 billion, decisively beating consensus estimates. This performance, driven by 13% volume growth across fifteen products with double-digit sales growth, prompted management to raise its full-year 2025 guidance for both earnings and revenue. Despite these strong fundamentals and a positive outlook revision, the stock traded down over 5%, indicating a significant disconnect between current performance and market sentiment. This negative reaction is attributed to an intense investor focus on the company's experimental weight-loss drug, MariTide. According to analyst commentary, the market is fixated on the drug's long-term potential and tolerability, key questions that will not be answered until data readouts in late 2025. While analysts reiterate an 'Outperform' rating, citing the strength of Amgen's broader portfolio and other clinical catalysts, the stock's volatility highlights that its near-term trajectory is being dictated by speculation around MariTide rather than its solid operational execution and headwinds from legacy products like the upcoming Prolia biosimilar.

Key Decisions for Investors

• Investors with a fundamental value focus may see the current share price weakness, despite a strong earnings beat and raise, as an attractive entry point based on the strength of the existing commercial portfolio.
• Traders and catalyst-driven investors should acknowledge that Amgen's stock is likely to remain highly volatile and tethered to sentiment around MariTide, with a long holding period until the key data readout in late 2025.
• It is critical to monitor upcoming clinical catalysts over the next 6-12 months and developments related to the Prolia/Xgeva biosimilar launch, as these will be significant drivers of value outside the dominant weight-loss drug narrative.